CDC Director is Wrong Re Myocarditis Numbers 5-11 & CDC Cannot Count Vaccine Doses - Huge Blunders!
What this video covers
In this December 2021 video, Prasad disputes the CDC’s public estimates of myocarditis risk in children aged 5–11 after COVID vaccination, shortly after the Pfizer vaccine was authorized for that age group. His core claim is methodological: he argues the CDC could not accurately count how many vaccine doses had actually been administered, making any rate calculation built on that denominator unreliable.
The video is built around two specific episodes from December 2021. First, the contradiction: on December 10, CDC Director Rochelle Walensky told ABC News, regarding myocarditis in 5- to 11-year-olds, “we haven’t seen anything yet,” touting the agency’s “incredibly robust vaccine safety system.” Days later, at a December 16 CDC meeting, the agency’s own slide showed that as of December 10 — the same day as the interview — there were 8 reports meeting the CDC’s working case definition for myocarditis out of 7.1 million doses administered. Prasad argues the director either did not know her own agency’s analyses or mischaracterized them, and that neither explanation was acceptable. Second, the counting failure: he cites Bloomberg and Axios reporting that the CDC had lowered the share of Americans 65 and older with at least one shot from 99.9% to 95% without changing raw shot totals, with Pennsylvania’s estimate exceeding the state’s own count by 850,000 doses. He quotes a Philadelphia public-health spokesperson saying, “we don’t have any faith in the numbers on the CDC website.”
Prasad argues that if the denominator (doses given) is uncertain, the resulting myocarditis rate is uncertain too — and he contends the agency was presenting precise-sounding safety figures on shaky foundations. The video fits into his broader late-2021 campaign questioning whether the risk-benefit balance justified vaccinating young children, who he argues faced very low risk from COVID itself.
The chronicle notes the context: CDC’s safety surveillance drew on multiple systems (VAERS, Vaccine Safety Datalink, v-safe), and agency officials defended their estimates as the best available from the largest vaccine-safety monitoring effort in U.S. history. Independent researchers later noted that myocarditis estimates did vary widely across studies depending on methodology and case ascertainment — which is the terrain Prasad was arguing on — though most analyses still found the risk rare and typically mild in younger children.
Key points
- Prasad argues the CDC’s myocarditis estimates for 5- to 11-year-olds rested on an unreliable count of administered doses, making the rate calculation suspect.
- He contrasts Walensky’s December 10, 2021 ABC statement — “we haven’t seen anything yet” on myocarditis in 5–11s — with the CDC’s own December 16 slide showing 8 reports meeting its working case definition out of 7.1 million doses, data-halted the day of the interview.
- On the counting failure, he cites Bloomberg/Axios reporting that the CDC cut estimated 65+ at-least-one-shot coverage from 99.9% to 95%, with Pennsylvania’s estimate exceeding the state’s by 850,000 doses, and quotes a Philadelphia official: “we don’t have any faith in the numbers on the CDC website.”
- According to Prasad, the agency presented precise-sounding safety figures without an accurate denominator.
- He connects the dispute to his broader argument that the risk-benefit case for vaccinating young children was not established.
- Prasad frames the episode as an example of the CDC overstating the certainty of its safety data.
- The chronicle notes CDC officials defended their multi-system surveillance (VAERS, Vaccine Safety Datalink, v-safe) as the best available monitoring.
- Later independent analyses did find myocarditis estimates varied by methodology, though most characterized the risk in young children as rare.